Skip to content

Study · Case report or series · n = 1 · 2025

4 results

Long-acting GH Use in Patients With Adult GH Deficiency Coexisting With Type 1 Diabetes Mellitus.

Higuchi Y, Bando H, Yamamoto M, Hirota Y, Ogawa W, Fukuoka H

JCEM case reports25 Sept 2025

PMID41018171 (opens in a new tab)PMCIDPMC12461574 (opens in a new tab)DOI10.1210/jcemcr/luaf214 (opens in a new tab)PepBankPUB-41018171
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanCase report or seriesSafety outcome

    In a man with hypopituitarism and T1DM, frequent hypoglycemia after switching to somapacitan led to an emergency department visit.

    In plain wordsIn a man with T1DM, frequent low blood glucose after switching to somapacitan led to an emergency department visit.

    Peptide
    Somapacitan
    Outcome
    Not applicableFrequent hypoglycemia
    Study

    n = 1

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Soon thereafter, he experienced frequent hypoglycemia, which led to an emergency department visit.
    1 context sentence
    Summary · context
    A 50-year-old man with hypopituitarism and T1DM switched from somatropin to somapacitan at his request.
  2. 02HumanCase report or seriesOther

    In a man with T1DM receiving somapacitan, weekly glucose fluctuations correlated with GH levels.

    In plain wordsIn a man with T1DM receiving somapacitan, weekly glucose fluctuations were linked to GH levels.

    Peptide
    Somapacitan
    Outcome
    Not applicableWeekly glucose fluctuations
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Continuous glucose monitoring revealed weekly glucose fluctuations, which correlated with GH levels.
    1 context sentence
    Summary · context
    A 50-year-old man with hypopituitarism and T1DM switched from somatropin to somapacitan at his request.
  3. 03HumanCase report or seriesOther

    In a man with T1DM receiving somapacitan, serum free fatty acids followed a parallel trend to weekly glucose fluctuations.

    In plain wordsIn a man with T1DM receiving somapacitan, blood fatty acids followed a trend parallel to weekly glucose fluctuations.

    Peptide
    Somapacitan
    Outcome
    Not applicableFree fatty acid fluctuations
    Study

    n = 1

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Serum free fatty acids showed a parallel trend.
    2 context sentences
    Summary · context
    Continuous glucose monitoring revealed weekly glucose fluctuations, which correlated with GH levels.
    Summary · context
    A 50-year-old man with hypopituitarism and T1DM switched from somatropin to somapacitan at his request.
  4. 04HumanCase report or seriesOther

    In a man with T1DM, insulin titration remained necessary despite increasing somapacitan dose.

    In plain wordsIn a man with T1DM, insulin dose changes remained necessary despite increasing somapacitan dose.

    Peptide
    Somapacitan
    Outcome
    Not applicableInsulin titration requirement
    Study

    n = 1

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Despite increasing the somapacitan dose, insulin titration was still required to stabilize glycemic variability.
    1 context sentence
    Summary · context
    A 50-year-old man with hypopituitarism and T1DM switched from somatropin to somapacitan at his request.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.